C., L., L., D., Y., W., T., M., A., I., R., R., . . . J., Y. (2017). Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
استشهاد بنمط شيكاغوC., Lee, et al. Gefitinib or Erlotinib Vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. 2017.
MLA استشهادC., Lee, et al. Gefitinib or Erlotinib Vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. 2017.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.